Thalidomide-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology
18(17):4806-19
7aR)-7a-methyl-1-[(2R)-6-(²H₃)methyl(7
3-dimethyl-1-oxobutan-2-yl]carbamoyl}-3
BMS-509744 reduces HIV infection of primary CD4+ T cells and attenuates the establishment of HIV infection in vitro
SAR405838 atel Thalidomide-PEG3-NH2 is a synthesized E3SAR405838 is a highly potent and selective MDM2 inhibitor, binds to MDM2 with Ki= 0. 88 nM and has high specificity over other proteins. IC50 value: 0. 88 nM (Ki) [1] Target: MDM2 in vitro: SAR405838 potently inhibits cell growth in cancer cell lines, including SJSA 1 (IC50, 0. 092 M), RS4; 11 (IC50, 0. 089 M), LNCaP (IC50, 0. 27 M), and HCT 116 (IC50, 0. 20 M) cells, and displays high selectivity over cancer cell lines with mutated or deleted p53,